Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ProShares Ultra Semiconductors (USD) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

ProShares Ultra SemiconductorsTrade
State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

ProShares Ultra Semiconductors vs State Street SPDR S&P Biotech ETF — how do they compare? ProShares Ultra Semiconductors trades at $89.08, while State Street SPDR S&P Biotech ETF trades at $159.93. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, ProShares Ultra Semiconductors nearer its low. Which is the better fit depends on your goals.

USDXBI
Sector
Leveraged / InverseBroad Market / Factor
52-Week High
$113.53$169.55
52-Week Low
$43.19$93.43

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ProShares Ultra Semiconductors

USD stock trades at $89.70, up 1.01% with bullish technical signals from moving averages. The company announced a dividend of $0.14 per share scheduled for June 2026. Technical indicators show strong support at $88 and resistance at $92, with RSI levels in neutral territory suggesting balanced momentum.

The stock shows technical strength but lacks current fundamental data for comprehensive valuation. The upcoming dividend provides income appeal, though investors face uncertainty without recent financial metrics. Market sentiment appears cautiously optimistic given the technical setup and corporate action.

State Street SPDR S&P Biotech ETF

XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.

Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ProShares Ultra Semiconductors

USD is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Semiconductors™ Index. It is a tactical instrument designed for sophisticated traders looking to magnify short-term bullish views on the U.S. semiconductor industry, specifically focusing on large-cap leaders in the chip and equipment space.

Read more on USD

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.

Read more on XBI